We are live on ! Find out more
HWAM

Hennion & Walsh Asset Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 41.95%
This Fund
S&P 500
This Quarter Est. Return
+8.4%
1 Year Est. Return
+41.95%
3 Year Est. Return
+93.92%
5 Year Est. Return
+100.55%
10 Year Est. Return
AUM
$2.48B
AUM Growth
+$226M
Cap. Flow
+$94.9M
Cap. Flow %
3.83%
Top 10 Hldgs %
18.66%
Holding
956
New
89
Increased
439
Reduced
377
Closed
40

Sector Composition

Rank Sector Weight
1 Technology 12.64%
2 Financials 10.39%
3 Healthcare 9.29%
4 Industrials 6.6%
5 Consumer Discretionary 3.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BCRX icon
701
BioCryst Pharmaceuticals
BCRX
$2.64B
$452K 0.02%
+50,455
New +$470K
TATT icon
702
TAT Technologies
TATT
$491M
$452K 0.02%
+14,795
New +$426K
CMPS
703
Compass Pathways
CMPS
$1.81B
$450K 0.02%
160,767
-7,427
-4% -$28K
CMF icon
704
iShares California Muni Bond ETF
CMF
$4.62B
$449K 0.02%
8,058
+2,035
+34% +$113K
ARVN icon
705
Arvinas
ARVN
$588M
$449K 0.02%
60,966
-911
-1% -$6.71K
VERA icon
706
Vera Therapeutics
VERA
$2.17B
$448K 0.02%
+18,997
New +$427K
KRYS icon
707
Krystal Biotech
KRYS
$9.68B
$447K 0.02%
3,253
-6,952
-68% -$1.02M
AVDL
708
DELISTED
Avadel Pharmaceuticals
AVDL
$445K 0.02%
+50,336
New +$442K
IBB icon
709
iShares Biotechnology ETF
IBB
$9.81B
$444K 0.02%
3,510
REXR icon
710
Rexford Industrial Realty
REXR
$8.07B
$442K 0.02%
12,424
+525
+4% +$18.3K
TOST icon
711
Toast
TOST
$20.2B
$442K 0.02%
+9,970
New +$392K
TGT icon
712
Target
TGT
$69.2B
$440K 0.02%
4,456
-12
-0.3% -$1.15K
RNST icon
713
Renasant Corp
RNST
$3.92B
$436K 0.02%
+12,142
New +$405K
CI icon
714
Cigna
CI
$72.4B
$433K 0.02%
1,310
+98
+8% +$31.6K
NVCR icon
715
NovoCure
NVCR
$2.06B
$433K 0.02%
+24,320
New +$424K
UIS icon
716
Unisys
UIS
$205M
$432K 0.02%
95,418
+19,920
+26% +$89.6K
HNW
717
DELISTED
Pioneer Diversified High Income Fund
HNW
$430K 0.02%
+34,396
New +$412K
PR
718
Permian Resources
PR
$18B
$430K 0.02%
31,578
-743
-2% -$9.56K
CXM icon
719
Sprinklr
CXM
$1.61B
$429K 0.02%
50,673
+14,232
+39% +$114K
CLDX icon
720
Celldex Therapeutics
CLDX
$3.48B
$428K 0.02%
+21,054
New +$410K
MD icon
721
Pediatrix Medical
MD
$2.12B
$424K 0.02%
+29,548
New +$405K
QURE icon
722
uniQure
QURE
$3.12B
$423K 0.02%
+30,369
New +$408K
ETR icon
723
Entergy
ETR
$49.7B
$423K 0.02%
5,085
+1,979
+64% +$163K
KBWP icon
724
Invesco KBW Property & Casualty Insurance ETF
KBWP
$269M
$423K 0.02%
+3,440
New +$417K
MLYS icon
725
Mineralys Therapeutics
MLYS
$2.41B
$421K 0.02%
+31,095
New +$451K

Similar funds

Hennion & Walsh Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Hennion & Walsh Asset Management held 956 positions worth $2.48B, up 10% from $2.25B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Hennion & Walsh Asset Management deployed $94.9M of net new capital in Q2 2025, opening 89 new positions and adding to 439 existing holdings. Its largest new stake was iShares Preferred and Income Securities ETF: 700,414 shares worth $21.5M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 11% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was Global X US Preferred ETF, an estimated $29.1M trimmed.

  • Hennion & Walsh Asset Management's largest Q2 2025 buy was iShares Preferred and Income Securities ETF: 700,414 shares worth $21.5M.
  • Hennion & Walsh Asset Management added most to iShares International Select Dividend ETF in Q2 2025, an estimated $5.17M increase.
  • Hennion & Walsh Asset Management's biggest Q2 2025 reduction was Global X US Preferred ETF, cutting an estimated $29.1M.
  • Hennion & Walsh Asset Management fully exited Insmed in Q2 2025, selling an estimated $2.72M.
  • Hennion & Walsh Asset Management's ten largest holdings make up 19% of its $2.48B portfolio in Q2 2025.
  • Hennion & Walsh Asset Management opened 89 new positions and closed 40 in Q2 2025.
  • Hennion & Walsh Asset Management's portfolio value rose 10% quarter-over-quarter to $2.48B.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.